Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
S.S.ORGANICS ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
S.S.ORGANICS Mar-23 |
ADCOCK INGRAM Jun-14 |
S.S.ORGANICS/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 41 | 325 | - | |
Low | Rs | 21 | 234 | - | |
Sales per share (Unadj.) | Rs | 21.8 | 96.6 | - | |
Earnings per share (Unadj.) | Rs | -8.1 | -24.3 | - | |
Cash flow per share (Unadj.) | Rs | -6.7 | -20.2 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | -32.5 | 75.8 | - | |
Shares outstanding (eoy) | m | 14.20 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.4 | 2.9 | 48.7% | |
Avg P/E ratio | x | -3.8 | -11.5 | 32.9% | |
P/CF ratio (eoy) | x | -4.6 | -13.9 | 33.1% | |
Price / Book Value ratio | x | -0.9 | 3.7 | -25.7% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 437 | 47,183 | 0.9% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 11 | 2,961 | 0.4% | |
Avg. sales/employee | Rs Th | 0 | 3,798.6 | - | |
Avg. wages/employee | Rs Th | 0 | 689.8 | - | |
Avg. net profit/employee | Rs Th | 0 | -957.2 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 310 | 16,307 | 1.9% | |
Other income | Rs m | 0 | 114 | 0.2% | |
Total revenues | Rs m | 310 | 16,421 | 1.9% | |
Gross profit | Rs m | -79 | -2,826 | 2.8% | |
Depreciation | Rs m | 21 | 704 | 2.9% | |
Interest | Rs m | 15 | 442 | 3.4% | |
Profit before tax | Rs m | -114 | -3,857 | 2.9% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2 | 241 | 0.8% | |
Profit after tax | Rs m | -116 | -4,109 | 2.8% | |
Gross profit margin | % | -25.3 | -17.3 | 146.2% | |
Effective tax rate | % | -1.7 | -6.2 | 27.9% | |
Net profit margin | % | -37.3 | -25.2 | 148.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 250 | 11,944 | 2.1% | |
Current liabilities | Rs m | 298 | 6,720 | 4.4% | |
Net working cap to sales | % | -15.5 | 32.0 | -48.5% | |
Current ratio | x | 0.8 | 1.8 | 47.2% | |
Inventory Days | Days | 16 | 111 | 14.3% | |
Debtors Days | Days | 119,672,906 | 124 | 96,557,471.6% | |
Net fixed assets | Rs m | 293 | 6,962 | 4.2% | |
Share capital | Rs m | 142 | 76 | 187.6% | |
Net worth | Rs m | -462 | 12,799 | -3.6% | |
Long term debt | Rs m | 630 | 4,498 | 14.0% | |
Total assets | Rs m | 543 | 24,179 | 2.2% | |
Interest coverage | x | -6.6 | -7.7 | 85.9% | |
Debt to equity ratio | x | -1.4 | 0.4 | -388.2% | |
Sales to assets ratio | x | 0.6 | 0.7 | 84.7% | |
Return on assets | % | -18.6 | -15.2 | 122.5% | |
Return on equity | % | 25.0 | -32.1 | -78.0% | |
Return on capital | % | -58.8 | -19.8 | 296.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -16 | 1,392 | -1.2% | |
From Investments | Rs m | -96 | -427 | 22.6% | |
From Financial Activity | Rs m | 112 | 4,082 | 2.7% | |
Net Cashflow | Rs m | 0 | 5,047 | -0.0% |
Compare S.S.ORGANICS With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare S.S.ORGANICS With: FABINO LIFE BDH INDUS. VENUS REMEDIES COLINZ LABOR J.B.CHEMICALS
Asian stocks inched higher on Tuesday as investors awaited a slew of economic data, corporate earnings and the U.S. Federal Reserve's policy meeting.